Mesoblast announced that Novartis has signed a partnership with the company to develop remestemcel-L for acute respiratory distress syndrome (ARDS), whether or not the ARDS was caused by COVID-19. This is an important validation of both the platform as well as its application in the treatment of respiratory disease. Novartis will make a US$25m upfront payment and an additional US$25m equity investment. Mesoblast may receive a total of US$505m in development milestones, an additional US$750m in s ....
30 Nov 2020
Mesoblast - Novartis licenses ARDS program
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Mesoblast - Novartis licenses ARDS program
Mesoblast Limited (MSB:ASX) | 0 0 -2.3% | Mkt Cap: 591.5m
- Published:
30 Nov 2020 -
Author:
Maxim Jacobs -
Pages:
6
Mesoblast announced that Novartis has signed a partnership with the company to develop remestemcel-L for acute respiratory distress syndrome (ARDS), whether or not the ARDS was caused by COVID-19. This is an important validation of both the platform as well as its application in the treatment of respiratory disease. Novartis will make a US$25m upfront payment and an additional US$25m equity investment. Mesoblast may receive a total of US$505m in development milestones, an additional US$750m in s ....